O’Brien et al. [220] showed that prophylactic administration of granulocyte–colony stimulating factor (G-CSF) to patients treated with FA may reduce the incidence of pneumonia, but does not interfere with the infections. Here, CSF3 is linked to susceptibility to pneumonia measurement.